GLP-1 drug manufacturers (e.g., Nova Nordisk, Eli Lilly)

Pharmaceutical companies producing GLP-1 drugs for weight management and metabolic health.

Why It Works

These drugs address significant health issues and have transformative potential for obesity and related conditions.

Revenue & Traction

Not mentioned in the transcript, but indicated to have a growing market cap.

Founding Story

Not mentioned in the transcript.

Business Playbook

Leveraging scientific advancements to create effective treatments for chronic health issues.

Why this works now

Eli Lilly's Mounjaro, a GLP-1 receptor agonist, provides a specific mechanism for addressing obesity through appetite regulation and glucose metabolism. The company effectively used direct-to-consumer advertising via social media platforms like Instagram to generate initial revenue and awareness. A significant risk for Eli Lilly is the regulatory scrutiny surrounding pharmaceutical marketing, which can complicate promotional strategies and delay product launches.

Additional Information

The speaker argues that GLP-1 drugs could have a substantial impact on American healthcare costs.

Source

Podcast: My First Million

Episode: Asking Scott Galloway 10 Questions We’re Not Allowed To Ask (unfiltered)

Creation Date: February 16, 2026

Ideas worth reading next

More case studies

More case studies from My First Million

See all My First Million coverage →